Volume spike: UOM.MU AS Latvijas Juras medicinas centrs (MUN) Mar 2026 EUR 7.40

UOM.MU stock triggered a clear volume spike during market hours as trades lifted intraday volume to 9,750 and price slid to €7.40, down 5.73% on Mar 2026. The surge in activity came with an unusually high relative volume reading of 43,875.44, suggesting concentrated buying and selling interest. Traders should note the stock trades on the MUN exchange in Germany and sits between its 50-day average of €8.44 and 200-day average of €7.08. We examine what drove the spike, how fundamentals align with the move, and short- and medium-term scenarios.

UOM.MU stock: Volume spike and intraday movement

The immediate driver is a volume spike to 9,750 shares against no reported avgVolume, producing a relVolume of 43,875.44. The stock opened at €7.40, matching the day low and closing below the prior close of €7.85. That sharp intraday volume concentrated at a lower price suggests liquidity events or block trades rather than steady accumulation. Market participants should monitor order-book prints and MUN trading notices for block trades or corporate updates.

Price action and technical read

Price is €7.40, year high €9.20, year low €6.00, and momentum measures are weak. The MACD histogram is -0.05 and ADX reads 100.00, signalling a strong trending move. Bollinger Band mid is €8.16 with a lower band at €7.60, so the stock trades below the 20-day midpoint. Short-term resistance cluster sits at the 50-day average €8.44 and support at the 200-day average €7.08.

Given the CCI of -296.06 and Williams %R at -100.00, technicals show oversold momentum on high volume—conditions that can precede short squeezes or continued distribution depending on news flow.

Fundamentals, valuation and sector context

AS Latvijas Juras medicinas centrs reports EPS €0.57 and a market cap of €5,920,000 with 800,000 shares outstanding. The simple PE from the quote is 12.98, while deeper TTM metrics show a price/book near 0.94 and price/sales 0.58. Free cash flow yield is 6.56% and dividend per share is €0.10.

In Healthcare, peers show an average PE of 29.42. UOM.MU’s lower valuation ratios point to value characteristics, but the current current ratio 0.86 and operating cash flow softness require attention. Fundamentals explain why some investors view the stock as a selective value play despite recent volatility.

Meyka AI grade, forecasts and price targets

Meyka AI rates UOM.MU with a score out of 100: 72.01 (Grade B+) with a suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Meyka AI’s forecast model projects a monthly figure of €7.46, a quarterly target of €9.86, and a 12-month target of €9.12. Versus the current €7.40, the model implies a 12-month upside of 23.26% and a quarterly upside of 33.24%. Short-term intraday target for active traders: €7.50; realistic 12-month price target: €9.12; 3-year target: €12.10. Forecasts are model-based projections and not guarantees.

Risks, trading strategy and liquidity notes

High relative volume can hide thin-market risk. With market cap €5.92M and daily trades small, slippage and wide spreads are possible. Debt metrics show 0.00 debt to equity, but the current ratio 0.86 flags short-term liquidity pressure. For volume-spike traders, set limit orders, size positions for thin liquidity, and use stop-loss levels near €6.80 for risk control.

Sector headwinds or a lack of analyst coverage can prolong volatility. Watch company releases and MUN trade notices before increasing exposure.

Final Thoughts

Key takeaways: UOM.MU stock moved on a clear volume spike to 9,750 shares with a large relative volume of 43,875.44, pushing price to €7.40 during market hours on Mar 2026. Technical indicators show oversold momentum, while valuation metrics (PE 12.98, PB 0.94) paint a value case versus a Healthcare sector average PE of 29.42. Meyka AI rates the stock 72.01/100 (B+, BUY) and projects a 12-month model target of €9.12, implying an upside of 23.26% versus the current price. For traders the priority is liquidity management: use limit orders and monitor block-trade reports on MUN. For investors, the combination of modest earnings, positive free cash flow yield 6.56%, and a low price/book supports a watch-buy approach, but the low current ratio and thin market cap keep the risk profile elevated. For more data and live updates see the company site and profile pages and our internal analysis on Meyka’s platform.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.